ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
AtaiBeckley Inc

AtaiBeckley Inc (ATAI)

5,19
0,31
(6,35%)
Geschlossen 05 Juli 10:00PM
5,19
0,00
(0,00%)
Nach Börsenschluss: 1:59AM

AtaiBeckley Inc (ATAI) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
5,19
( 6,35% )
Gebot
5,15
Fragen
5,19
Volumen
11.327.858
4,77 Tagesbereich 5,27
2,53 52-Wochen-Bereich 6,75
Marktkapitalisierung
Handelsende
4,88
Handelsbeginn
4,88
Letzter Handelszeitpunkt
Finanzvolumen
US$ 56.015.903
VWAP
4,945
Durchschnittliches Volumen (3 Mio.)
US$ 7.006.321
Ausgegebene Aktien
368.166.674
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-2
Gewinn pro Aktie (EPS)
-2,44
Erlöse (LTM)
3,49M
Nettogewinn (LTM)
-663,4M

Über AtaiBeckley Inc

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in... AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Hauptsitz
New York, United States
Gegründet
2026
AtaiBeckley Inc is listed in the Healthcare sector of the NASDAQ with ticker ATAI. The last closing price for AtaiBeckley was US$4,88. Over the last year, AtaiBeckley shares have traded in a share price range of US$ 2,53 to US$ 6,75.

AtaiBeckley currently has 368.166.674 shares in issue. The market capitalisation of AtaiBeckley is US$1,91 billion. AtaiBeckley has a price to earnings ratio (PE ratio) of -2.00.

Option-Flow AtaiBeckley (ATAI)

Gesamtfluss

Bullisch

Nettoprämie

108k

Calls / Puts

100,00%

Käuf. / Verkä.

0,00%

OTM / ITM

200,00%

Sweeps

0,00%

ATAI Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
11.0425.06024096394.155.524.15202498875.18533962CS
40.6915.33333333334.55.523.670193059184.6858753CS
121.4338.03191489363.765.523.56572352294.53697266CS
26123.86634844874.195.523.26556272874.23348143CS
522.2375.33783783782.966.752.5355460174.3906674CS
1563.44196.5714285711.756.751.02528695983.47996288CS
260-12.7-70.989379541617.8920.451.02520785643.67525528CS

ATAI - Frequently Asked Questions (FAQ)

What is the current AtaiBeckley Inc share price?
The current share price of AtaiBeckley Inc is US$ 5,19
How many AtaiBeckley Inc shares are in issue?
AtaiBeckley Inc has 368.166.674 shares in issue
What is the market cap of AtaiBeckley Inc?
The market capitalisation of AtaiBeckley Inc is USD 1,91B
What is the 1 year trading range for AtaiBeckley Inc share price?
AtaiBeckley Inc has traded in the range of US$ 2,53 to US$ 6,75 during the past year
What is the PE ratio of AtaiBeckley Inc?
The price to earnings ratio of AtaiBeckley Inc is -2
What is the cash to sales ratio of AtaiBeckley Inc?
The cash to sales ratio of AtaiBeckley Inc is 515,1
What is the registered address of AtaiBeckley Inc?
The registered address for AtaiBeckley Inc is 250 West 34th Street, New York, New York, 10119
What is the AtaiBeckley Inc website address?
The website address for AtaiBeckley Inc is www.ataibeckley.com
Which industry sector does AtaiBeckley Inc operate in?
AtaiBeckley Inc operates in the Biotechnology & Life Sciences sector

ATAI Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen